Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: Is it safe even in cancer patients?

Lino Del Pup, Raffaele Di Francia, Carla Cavaliere, Gaetano Facchini, Giorgio Giorda, Paolo De Paoli, Massimiliano Berretta

Research output: Contribution to journalArticle

Abstract

Urogenital symptoms resulting from estrogen deficiency are common problems that impair quality of life and sexuality. Potentially, one out of three postmenopausal women could benefit from a vaginal estrogen therapy, but the fear of systemic absorption limits its use. Promestriene used vaginally to relieve vaginal atrophy is a locally effective estrogen that has not shown systemic estrogenic effects. Thus, it could be a first-line option for those who necessitate a minimal or ideally no vaginal absorption, particularly in symptomatic cancer patients. There are little data available in the literature, mostly consisting of small, open-label, short duration studies, and few randomized-controlled studies. After a long-term market experience (almost 40 years), in 34 countries, and millions of pieces prescribed, the side effects were very rarely reported in pharmacovigilance data, whereas the effectiveness to relieve atrophy was good. To further improve promestriene safety, especially in estrogen-sensitive cancer patients, a very low dose is used from the beginning, starting from half or less of the usual dose, and then gradually increased till the minimum effective dose, which could further reduce its already minimal vaginal absorption.

Original languageEnglish
Pages (from-to)989-998
Number of pages10
JournalAnti-Cancer Drugs
Volume24
Issue number10
DOIs
Publication statusPublished - Nov 2013

Keywords

  • absorption
  • cancer
  • promestriene
  • systemic effects
  • vaginal atrophy
  • vaginal estrogens

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: Is it safe even in cancer patients?'. Together they form a unique fingerprint.

  • Cite this